Latest Healthcare It News

Green Cross Health (NZX: GXH) has acknowledged discussions with third parties about a possible sale of its Medical division but emphasised that no transaction is guaranteed. The company remains committed to updating shareholders as the situation develops.

Insignia Financial Limited will be removed from the S&P/ASX 200 Index ahead of its acquisition by Daintree BidCo, with 4DMedical Limited stepping in on April 20, 2026.

Pro Medicus has secured a 5-year, A$37 million contract renewal with Northwestern Medicine, featuring higher minimum usage commitments and increased fees per transaction, reflecting growth in exam volumes.

Pacific Edge reported a 2.7% increase in test volumes for Q4 2026 despite operational challenges, supported by growing momentum toward Medicare coverage and expanded commercial payer adoption in the US and Asia Pacific.

Elanor Investors Group posted a net loss after tax of $13.8 million for the half year ended 31 December 2025, with no interim distribution declared. The group is progressing a strategic recapitalisation with Rockworth Capital Partners to strengthen its balance sheet amid ongoing financial challenges and material uncertainty about its ability to continue as a going concern.

EBR Systems has reported a significant increase in commercial implantations of its WiSE System in Q1 2026, more than doubling case volumes from the previous quarter and projecting preliminary revenue between US$2.25 million and US$2.36 million.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals has broadened availability of DAYBUE STIX, a new FDA-approved powder formulation of trofinetide for Rett syndrome, in the US. Early caregiver feedback and expert consensus highlight its potential role in personalised patient care.

Pro Medicus Limited’s U.S. subsidiary has signed a five-year, A$23 million contract to implement its cloud-based Visage 7 Enterprise Imaging Platform across the University of Maryland Medical System. The rollout is planned to begin immediately, with go-live targeted for early 2027.

Memphasys Limited (ASX: MEM) announced an investor webinar and released an updated presentation detailing its transition from early-stage commercialisation to scaling global revenues, highlighting multi-market sales, recurring cartridge revenue, and regulatory progress.

ImpediMed Limited has appointed Erik Anderson as its new CEO and Managing Director, effective 7 April 2026, aiming to boost commercial execution and revenue growth in the US market. Dr Parmjot Bains will remain as an advisor until 30 June 2026 to ensure a smooth leadership transition.

Vitura Health has appointed Justin James as its new CEO, bringing a wealth of healthcare leadership and a proven track record in specialty therapies to accelerate the company’s transformation.

Algorae Pharmaceuticals has reached a key regulatory milestone as the TGA accepts its initial registration dossier, paving the way for potential commercialisation of its generic medicines in Australia and New Zealand.